Search Results - "VOITK, JÜRI"

Implications of pulse wave velocity and central pulse pressure in heart failure with reduced ejection fraction by Kõre, Anette Caroline, Joonsalu, Tuuli, Serg, Martin, Pauklin, Priit, Voitk, Jüri, Roose, Indrek, Eha, Jaan, Kampus, Priit

“…Carotid-femoral pulse wave velocity (cfPWV) and central pulse pressure (PP) are recognised as significant indicators of vascular health and predictors of…”
Get full text

Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention by Antman, Elliott M., MD, FACC, Wiviott, Stephen D., MD, Murphy, Sabina A., MPH, Voitk, Juri, MD, FACC, Hasin, Yonathan, MD, Widimsky, Petr, MD, DrSc, Chandna, Harish, MBBS, FACC, Macias, William, MD, PhD, McCabe, Carolyn H., BS, Braunwald, Eugene, MD, MACC

“…Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A TRITON–TIMI 38 (TRial to Assess…”
Get full text

Reduction of inappropriate implantable cardioverter-defibrillator therapies using enhanced supraventricular tachycardia discriminators: the ReduceIT study by Geller, Johann Christoph, Wöhrle, Armin, Busch, Mathias, Elsässer, Albrecht, Kleemann, Thomas, Birkenhauer, Frank, Bramlage, Peter, Veltmann, Christian

“…Purpose Inappropriate implantable cardioverter-defibrillator (ICD) shocks are associated with greater healthcare resource utilization, poorer quality-of-life,…”
Get full text

Diagnosis and treatment of acute myocardial infarction in tertiary and secondary care hospitals in Estonia by AINLA, TIIA, MARANDI, TOOMAS, TEESALU, REIN, BABURIN, ALEKSEI, ELMET, MÄRT, LIIVER, ANITA, PEEBA, MARGUS, VOITK, JÜRI

“…Aim: To compare validity of AMI diagnosis and treatment of AMI patients between tertiary and secondary care hospitals in Estonia. Methods: Two tertiary and…”
Get full text

Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention : A TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) Analysis by ANTMAN, Elliott M, WIVIOTT, Stephen D, MURPHY, Sabina A, VOITK, Juri, HASIN, Yonathan, WIDIMSKY, Petr, CHANDNA, Harish, MACIAS, William, MCCABE, Carolyn H, BRAUNWALD, Eugene

“…We evaluated the relative contributions of the loading and maintenance doses of prasugrel on events in a TRITON-TIMI 38 (TRial to Assess Improvement in…”
Get full text

No evidence of automatic atrial overdrive pacing efficacy on reduction of paroxysmal atrial fibrillation by de Voogt, Willem, van Hemel, Norbert, de Vusser, Philip, Mairesse, Georges H., van Mechelen, Rob, Koistinen, Juhani, van den Bos, Arjan, Roose, Indrek, Voitk, Jüri, Yli-Mäyry, Sinikka, Stockman, Dirk, El Allaf, Dia, Tse, Hung-Fat, Lau, Chu-Pak

“…Aims Paroxysmal atrial fibrillation (PAF) is frequently encountered in pacemaker patients, most commonly in sick sinus syndrome. The combination of…”
Get full text

Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial by Nicolau, André M, Corbalan, Ramon, Nicolau, Jose C, Ruff, Christian T, Zierhut, Wolfgang, Kerschnitzki, Michael, Duris, Tibor, Juul-Möller, Steen, Voitk, Juri, Trevisan, Marco, Nordio, Francesco, Antman, Elliott M, Giugliano, Robert P

“…Abstract Aims Non-vitamin K antagonist oral anticoagulants represent a new option for prevention of embolic events in patients with atrial fibrillation (AF)…”
Get full text

Abstract 16587: Edoxaban Associated With Fewer Serious Adverse Events and Lower Mortality Than Warfarin, Regardless of Burden of Comorbidities: Insights From the ENGAGE AF-TIMI 48 Trial by Corbalan, Ramon, Ruff, Christian, Duris, Tibor, Juul-Möller, Steen, Voitk, Juri, Trevisan, Marco, Antman, Elliott, Braunwald, Eugene, Giugliano, Robert

“…BackgroundAtrial fibrillation (AF) is more frequent in elderly pts and those with underlying cardiac and other comorbidities. The multicenter ENGAGE AF-TIMI 48…”
Get full text